Navigation Links
Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinson's Disease Research
Date:11/3/2008

NEW YORK, Nov. 3 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation today announced the availability of up to $11 million in 2009 funding for research toward transformative treatments and a cure for Parkinson's disease.

Funding is open to academic and industry researchers through the Foundation's Pipeline Programs, five separate initiatives that stoke research at every stage of the PD drug development pipeline. This includes early-stage discovery research, translational studies that can carry identified hits forward to the next stage of development, and proof-of-principle/first-in-human clinical trials.

"The Michael J. Fox Foundation is committed to prioritizing and aggressively driving research with potential to significantly improve patients' quality of life," said Katie Hood, the Foundation's CEO. "Each one of our Pipeline Programs is a unique and complementary expression of our overarching mission -- identifying and enabling the critical ideas, teams and projects that will carry the field over the finish line to make Parkinson's a disease of the past."

There are a total of five Pipeline Programs: three annually recurring initiatives known collectively as The Edmond J. Safra Core Programs for PD Research; Novel Approaches to Drug Discovery for PD, a collaboration made possible by co-funding from Elan (NYSE: ELN); and the industry-exclusive Therapeutics Development Initiative.

Brief program descriptions follow. Full details are available at http://www.michaeljfox.org/research.cfm. The Foundation has redesigned its Funding Opportunities page to enhance ease of use and provide researchers with a better understanding of how various programs fit into the larger context of the MJFF portfolio.

Rapid Response Innovation Awards, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

No deadline; applications accepted at any time

Rapid Response Innovation Awards provide up to $75,000 for projects with little to no existing preliminary data, but with potential to significantly impact understanding or treatment of Parkinson's disease. MJFF is eager to fund high-risk, high-reward projects tackling critical scientific roadblocks to open new avenues for PD therapy development. Research proposals may be submitted at any time and funding decisions are made within six weeks of receiving the application.

Target Validation, An Edmond J. Safra Core Program for PD Research

Total available funding: $2 million

Deadline: 6 p.m. ET, Tuesday, January 6, 2009

Funding anticipated: May 2009

Target Validation provides awards of up to $250,000 to validate the therapeutic potential of scientific discoveries and push them one step closer to the clinic. While research continues to identify new genetic, cellular and biological targets for therapeutic intervention to benefit PD patients, the translation of these discoveries into practical treatments requires additional applied work. Target Validation funds this work with the ultimate goal of 'de-risking' potential investment in the most promising targets by biotech and pharmaceutical companies, who are generally best-suited to carry promising therapies forward into the clinic.

Clinical Intervention Awards, An Edmond J. Safra Core Program for PD Research Total available funding: $3 million

An Edmond J. Safra Core Program for PD Research

Deadline: 6 p.m. ET, Thursday, March 12, 2009

Funding anticipated: July 2009

The Clinical Intervention Awards drive clinical intervention trials of promising therapeutic approaches with potential to significantly improve the treatment of PD. Ideal proposals will focus on tests of novel treatments that can slow or halt disease progression, or that can greatly reduce PD motor and non-motor symptoms beyond (and without the complications of) current standards of care. There is no pre-set budget limitation for applications under this initiative.

Novel Approaches to Drug Discovery for PD

A collaboration with Elan Pharmaceuticals, Inc.

Total available funding: $1.5 million

Deadline: 6 p.m. ET, Tuesday, February 10, 2009

Funding Anticipated: July 2009

With a strong focus on the development of disease-modifying therapies for PD, Novel Approaches to Drug Discovery provides funding for projects of up to one year's duration. Ideal proposals will focus on efforts to develop promising biological targets into novel disease-modifying therapeutic strategies. Novel Approaches holds unique potential to provide awardees from both academic and biotech institutions with a clear opportunity for follow-on funding and collaboration for further development. Elan Pharmaceuticals, Inc., a neuroscience-based biotechnology company committed to developing novel approaches for neurodegenerative diseases, has an option for a right of first negotiation for any promising approaches or materials that arise out of this program. There is no pre-set budget limitation for applications under this initiative.

Therapeutics Development Initiative

Total available funding: $2.5 million, exclusively to industry

Deadline: 6 p.m. ET, Tuesday, January 20, 2009

Funding Anticipated: June 2009

The Therapeutics Development Initiative (TDI) seeks to stimulate preclinical Parkinson's disease research projects of up to two years' duration at for-profit institutions. There is no pre-set budget limitation for applications under this initiative. The program prioritizes key and critical preclinical studies necessary for developing, optimizing and evaluating therapeutic strategies that if successful can move into human testing.

Applications for all programs must be submitted through http://www.michaeljfox.org.

Pre-proposals (required for all programs except Rapid Response Innovation Awards) will be reviewed by the Foundation's scientific staff and a panel of scientific experts. Applicants whose pre-proposals meet the review criteria will be invited to submit full proposals. For each program, a conference call with MJFF Research Programs staff to further clarify the aims and goals will be held in advance of the application deadline. Date and time details for each conference call are available at http://www.michaeljfox.org.

Additional research funds for the coming year will be announced at later dates under the Foundation's 2009 Critical Challenges initiatives -- programs that provide funding for top MJFF research priorities and areas of particular emphasis.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded $128 million in research to date.


'/>"/>
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ... reverse split of its issued and outstanding shares of ... Thursday, February 11, 2016. The Company,s common stock will ... 76303T308 and temporary ticker symbol "RCHAD". After 20 trading ... ticker symbol (RCHA).  --> ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC is ... medical professionals throughout the country. The Guard was specifically designed to handle each ... employee training, regulatory updates, and compliance coaching. , In addition to meeting the ...
(Date:2/10/2016)... FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... Best Water Brand. There were three leading bottled water brand owners that topped the ... services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a ...
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages ... Association™ (ALCA) to conduct a survey that takes a closer look at cases of ... the prevalence and causes of TBI among the aging population, and identifies the challenges ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Gout is ... and brings pain that is often severe, with intense swelling and redness. It is ... eight million people, but older adults are the most susceptible, according to the February ...
(Date:2/10/2016)... ... 2016 , ... AHRA: The Association for Medical Imaging Management ... will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, ... effectively communicate with their own organizational staff and leadership. , “I am ...
Breaking Medicine News(10 mins):